Treatment of advanced thyroid cancer: role of molecularly targeted therapies Lorinda L. CovellApar Kishor Ganti Review 28 January 2015 Pages: 311 - 324
The route to personalized medicine in bladder cancer: where do we stand? Francesco MassariChiara CiccareseGiampaolo Tortora Review 30 January 2015 Pages: 325 - 336
Targeting epidermal growth factor receptors and downstream signaling pathways in cancer by phytochemicals Onat KadiogluJingming CaoThomas Efferth Review 21 November 2014 Pages: 337 - 353
Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma Jianhong LiCynthia L. JacksonAli Amin Original Research 08 October 2014 Pages: 355 - 363
Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC) C. W. KwokO. TreeckJ. B. Engel Original Research 09 October 2014 Pages: 365 - 373
Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer Feby Ingriani MardjuadiJavier CarrascoJean-Pascal Machiels Original Research 11 October 2014 Pages: 375 - 383
Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry Katerina KubackovaZ. Bortlicekon behalf of the Czech Renal Cancer Cooperative Group Original Research 12 October 2014 Pages: 385 - 392
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition Simona CocoAnna TruiniFrancesco Grossi Original Research 25 October 2014 Pages: 393 - 404
Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack Marc CinciSrinivas MamidiMichael Kirschfink Original Research 15 November 2014 Pages: 405 - 413
Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping? M. A. AllardR. SaffroyA. Lemoine Original Research 26 November 2014 Pages: 415 - 421
Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T Ilya TsimafeyeuAnton SnegovoyLudmila Manzuk Original Research 04 December 2014 Pages: 423 - 427
Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib Yi Ling TeoXiu Ping ChueAlexandre Chan Original Research 13 December 2014 Pages: 429 - 437
Sunitinib does not attenuate contractile force following a period of ischemia in isolated human cardiac muscle Anna M. J. ThijsSaloua El MessaoudiGerard A. Rongen Original Research 23 December 2014 Pages: 439 - 443
Regorafenib: start low and go slow S. TabchiM. Ghosn Day-to-Day Practice 30 December 2014 Pages: 445 - 447